

## DAFTAR PUSTAKA

1. Ayu IG, Putri M, Dewa D, Sukrama M. Karakteristik Bakteri *Pseudomonas aeruginosa* dan Pola Kepekaannya Terhadap Antibiotik di Intensive Care Unit (Icu) RSUP Sanglah Pada Bulan November 2014–Januari 2015 Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Udayana Bagian Mikrob. E-Journal Med. 2019;8(4).
2. Lutpiatina L. Cemaran *Staphylococcus aureus* dan *Pseudomonas aeruginosa* pada Steteskop di Rumah Sakit. 2017;6(2):61–6.
3. Pradipta IS, Febrina E, Ridwan MH, Ratnawati R. Identifikasi Pola Penggunaan Antibiotik sebagai Upaya Pengendalian Resistensi Antibiotik Identification of Antibiotic Use Pattern as an Effort to Control Antibiotic Resistance. 2012;1:16–24.
4. Yuwono. Pandemi Resistensi Antimikroba: Belajar dari MRSA. J Kedokt dan Kesehat. 2010;1(42):2837–50.
5. van Bambeke F, Mingeot-Leclercq M-P, Glupczynski Y, Tulkens PM. Mechanisms of Action. Infect Dis (Auckl). 2017;1162-1180.e1.
6. CDC C for Disease Control and Prevention. *Pseudomonas aeruginosa*. 2017;2017–8.
7. Wolter DJ, Lister PD. Mechanisms of  $\beta$ -lactam Resistance Among *Pseudomonas aeruginosa* Mechanisms of  $\beta$ -lactam. 2015;(August 2012).
8. Lin S, Liu M, Lin C, Shi Z. Phenotypic Detection and Polymerase Chain Reaction Screening of Extended-Spectrum  $\beta$ -Lactamases Produced By *Pseudomonas aeruginosa* Isolates. J Microbiol Immunol Infect [Internet]. 2012;45(3):200–7.
9. Putri A, Rasyid R, Rahmatini. Artikel Penelitian Perbedaan Sensitivitas Kuman *Pseudomonas aeruginosa* Penyebab Infeksi Nosokomial Terhadap Beberapa Antibiotika. 2014;3(June 2013):327–31.
10. Jawetz, Melnick, Adelberg's. Medical Microbiology. 26th ed. McGraw-Hill. United States: The McGraw-Hill Companies, Inc; 2013. 245 p.
11. Siegrist. *Pseudomonas* a Communicative Bacteria *Pseudomonas* a Communicative Bacteria. 2010;2.
12. Alhazmi A. *Pseudomonas aeruginosa*–Pathogenesis and Pathogenic Mechanisms. 2018;(February).
13. Ribeiro A, Burth P, Rieken P, Rocco M, Castro-faria MV, Castro-faria-neto HC. International Journal of Medical Microbiology Possible Mechanisms of *Pseudomonas aeruginosa* Associated Lung Disease Cassiano Felipe

Gonc. 2016;306:20–8.

14. Anonim. Basic Pharmacology & Drugs Notes. edisi 2017. Makassar: MMN Publishing, Makassar; 2017. 396 p.
15. Utami RE. Antibiotika, Resistensi, dan Rasionalitas Terapi. 2011;1(4):191–8.
16. Kesehatan M, Indonesia R. Menteri Kesehatan Republik Indonesia. 2011
17. P R. Antibiotik Kedokteran Gigi. UB Press. 2019;118 p.
18. Nugroho AE. Farmakologi Obat-obat Penting dalam Pembelajaran Ilmu Farmasi dan Dunia Kesehatan. Yogyakarta: Pustaka Pelajar; 2012. 195–198 p.
19. Etebu E, Arikekpar I. Antibiotics : Classification and Mechanisms of Action with Emphasis on Molecular Perspectives. 2016;(January).
20. Kardos N, Demain AL. Penicillin : The Medicine with The Greatest Impact on Therapeutic Outcomes. 2011;677–87.
21. Kapoor G, Saigal S. Action and Resistance Mechanisms of Antibiotics : A Guide for Clinicians Action and Resistance Mechanisms of Antibiotics. 2017;(February 2018).
22. Agatha C, Liana P, Susilawati. Perbedaan Angka Kejadian Multidrug Resistant Organisms Tahun 2015 dan 2016 Pada Pasien Gicu Rsup Dr. Mohammad Hoesin Palembang Resistant Organisms (MDRO) adalah dunia diantaranya adalah Methicillin Resistant *Staphylococcus aureus* (MRSA), Vancomycin T. Sriwijaya, Maj Kedokt. 2018;
23. Wibowo JT. Resistensi Bakteri Patogen dan Strategi Mengatasi Bakteri Resisten. Oseana. 2015;XL:11–7.
24. Hilda, Berliana. Pola Resistensi Bakteri *Staphylococcus Aureus*. J Mahakam Husada. 2015;IV(1):11–7.
25. Negara KS. Analisis Implementasi Kebijakan Penggunaan Antibiotika Rasional Untuk Mencegah Resistensi Antibiotika di RSUP Sanglah Denpasar : Studi Kasus Infeksi Methicillin Resistant *Staphylococcus Aureus* Analysis The Implementation Policy of Rational Use of Antibiot. J Arsi. 2014;1 Nomor 1:42–50.
26. CDC C for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. Atlanta. 2013;37(12):31.
27. Dessy T. Frekuensi  $\beta$ -Lactamase Hasil *Staphylococcus aureus* Secara Iodometri Di Laboratorium Mikrobiologi Fakultas Kedokteran Universitas Andalas. J Gradien. 2014;10(2):992–5.
28. Pratiwi RH. Mekanisme Pertahanan Bakteri Patogen Terhadap Antibiotik. J

Pro-Life. 2017;4 Nomor 3.

29. Zango UU, Ibrahim M, Shawai AA, Shamsuddin M. A Review on  $\beta$ -lactam Antibiotic Drug Resistance. 2019;3(2):52–8.
30. Yuwono. Identifikasi Gen SHV pada *Enterobacteriaceae* Produsen Extended-Spectrum Beta Lactamases (ESBLs). Syifa' Medica. 2013;4(1).
31. Ihsan S, Akib NI. Studi Penggunaan Antibiotik Non Resep Di Apotek Komunitas Kota Kendari. Media Farm J Ilmu Farm. 2016;13(2):272–84.
32. Saudi AA, Rusdy. Uji Daya Hambat Antibiotika Terhadap Bakteri Penyebab Infeksi Saluran Kemih Di Rumah Sakit Salewangang Maros. Media Farm Poltekes Makassar. 2018;XV No. 2:27–8.
33. Gunardi WD. Mekanisme Biomolekuler *Pseudomonas aeruginosa* dalam Pembentukan Biofilm dan Sifat Resistensi terhadap Antibiotika. J Univ Kristen Krida Wacana. 2017;1–7.
34. Neal MJ. At a Glance Farmakologi Medis. Jakarta: Erlangga; 2006. 81 p.
35. Kang D, Sinuraya RK, Rostinawati T, Abdulah R, Farmakologi D, Farmasi F, et al. Mutasi Gen bla CTX-M sebagai Faktor Risiko Penyebab Resistensi Antibiotik Gene bla CTX-M Mutation as Risk Factor of Antibiotic Resistance. 2017;6(2).
36. Masyeni S, Sukmawati H, Siskayani AS, Dharmayanti S, Sari K. Antimicrobial Susceptibility Pattern of Pathogens Isolated from Various Specimens In Denpasar-Bali: A Two Years Retrospective Study. Biomed Pharmacol J. 2018;11(1):493–502.
37. Ahmed Hasan S, Mohamed Najati A SAK. Prevalence and Antibiotic Resistance of "*Pseudomonas aeruginosa*" Isolated from Clinical Samples In Kirkuk City, Iraq. EurAsian J Biosci. 2020;14(April):1821–5.
38. Lusa YH, Bawa E, Tijjani MB, Aliyu MS, Zango UU, Raji MIO. Antibiotics Susceptibility Pattern of *Pseudomonas aeruginosa* Isolated from Wounds in Patients Attending Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. 2012;20(1):32–4.
39. Anjum F, Mir A. Susceptibility Pattern of *Pseudomonas Aeruginosa* Against Various Antibiotics. 2010;4(May):1005–12.
40. Shidiki A, Raj Pandit B, Vyas A. Characterization and Antibiotic Profile of *Pseudomonas aeruginosa* Isolated from Patients Visiting National Medical College and Teaching Hospital, Nepal. Acta Sci Pharm Sci. 2019;3(7):02–6.
41. Khan J, Wahab A, Qayyum A, Jamshed S. Journal of Chemical and Pharmaceutical Research, 2014, 6 (11): 715-719 Research Article Drug Resistance Pattern of *Pseudomonas aeruginosa* Isolates at PIMS Hospital, Islamabad, Pakistan. 2014;6(11):715–9.



42. Senthamarai S, Suneel Kumar Reddy A, Sivasankari S, Anitha C, Somasunder V, Kumudhavathi MS, et al. Resistance Pattern of *Pseudomonas aeruginosa* In A Tertiary Care Hospital of Kanchipuram, Tamilnadu, India. *J Clin Diagnostic Res.* 2014;8(5):30–2.
43. Nikokar I, Tishayar A, Flakiyan Z, Alijani K, Rehana-banisaeed S. Antibiotic Resistance And Frequency of Class 1 Integrons Among *Pseudomonas aeruginosa*, Isolated From Burn Patients in Guilan, Iran. 2013;5(1):36–41.
44. Manikandan C, Amsath A. Original Research Article Antibiotic Susceptibility of Bacterial Strains Isolated from Wound Infection Patients in Pattukkottai, Tamilnadu, India. 2013;2(6):195–203.
45. Debnath S, Bhaumik D, Chakraborty M, Ghosh R, Das L, Bhattacharjee P. Antibiotic Sensitivity Pattern of Bacterial Isolates from Sputum Samples of Admitted Patients With Acute Lower Respiratory Tract Infections In A Tertiary Care Teaching Hospital of Tripura: a Hospital Record-Based Study. 2020;9(2):254–8.
46. Igbalajobi O, Oluyeye A, Oladeji A, Babalola J. Antibiotic Resistance Pattern of *Pseudomonas Aeruginosa* Isolated from Clinical Samples in Ekiti State University Teaching Hospital, Ado-Ekiti, Ekiti State of Nigeria. *Br Microbiol Res J.* 2016;12(4):1–6.
47. Babaeekhou L, Karshenasan H, Pishkar L. Antibiotic Resistance in Clinical Isolates of *Pseudomonas aeruginosa*: A New Viewpoint for Antibiotic Prescription. *Hamadan Univ Med Sci [Internet].* 2018;5(3):55–60. Available from: <https://doi.org/10.34172/ajcmi.2018.11>
48. Oladipo EK, Oloke JK, Omomowo IO, Oyeniran AO, Awoyelu EH, Ogundele SO. Incidence of cephalosporin resistance among clinical isolates of *Pseudomonas aeruginosa* in Ibadan, South-Western Nigeria. 2015;4(3).
49. Oladipo EK, Ogunsola JO, Akinade BS, Awoyelu EH. Resistance of Clinical Isolates to Generation of Cephalosporins in a Tertiary Hospital in Ogbomoso, South-Western Nigeria. *Res J Microbiol.* 2015;10(2):76–82.
50. Razvi N, Humayoon R. Resistance Pattern of 3<sup>rd</sup> Generation Cephalosporins. 2015;(May 2017).
51. Khalili-Samani M, Barati M, Mirmohammadsadegh N, Amin M, Samadikuchaksaraei A. Detection of Mutations of Antimutator Gene *pfpI* in *Pseudomonas aeruginosa* Species Isolated from Burn Patients in Tehran, Iran. *J Med Microbiol Infect Dis.* 2019;7(4):127–31.
52. Nassar MSM, Hazzah WA, Bakr WMK. Evaluation of antibiotic susceptibility test results: How guilty a laboratory could be? *J Egypt Public Health Assoc.* 2019;94(1):1–5.
53. Ochoa SA, López-Montiel F, Escalona G, Cruz-Córdova A, Dávila LB,

López-Martínez B, et al. Pathogenic Characteristics of *Pseudomonas aeruginosa* Strains Resistant To Carbapenems Associated With Biofilm Formation. *Bol Med Hosp Infant Mex.* 2013;70(2):138–50.

54. Meletis G, Bagkeri M. *Pseudomonas aeruginosa*: Multi-Drug-Resistance Development and Treatment Options. *Infect Control.* 2013;
55. Biutifasari V. Extended Spectrum Beta-Lactamase (ESBL). 2018;1(1):1–11.
56. Bramardipa AAB, Sukrama IDM, Budayanti NNS. Bacterial Pattern and its Susceptibility Toward Antibiotic on Burn Infection in Burn Unit Sanglah General Hospital. *Bali Med J.* 2019;8(1):328.
57. Rustini R, Jamsari J, Marlina M, Zubir N, Yuliandra Y. Antibacterial Resistance Pattern of *Pseudomonas aeruginosa* Isolated From Clinical Samples at A General Hospital in Padang, West Sumatra, Indonesia. *Asian J Pharm Clin Res.* 2017;10(8):158–60.
58. Rustini et. al. Coden (USA): Pchax Resistance Patterns *Pseudomonas aeruginosa* Isolated from Clinical Patient Samples. *Der Pharma Chem.* 2017;9(7):61–3.

